Chugai Pharmaceutical : Notice of Filing an Appeal in Patent Infringement Lawsuit concerning Edirol Capsule

	June 9, 2022
Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number:	4519 (Prime Market of Tokyo Stock Exchange)
Head office:	1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo
President & CEO:	Osamu Okuda
Inquiries to:	Toshiya Sasai
	Head of Corporate Communications Dept.
	Tel: [phone]

Notice of Filing an Appeal in Patent Infringement Lawsuit concerning

Edirol Capsule

Chugai Pharmaceutical Co., Ltd.announced that Chugai has appealed today to the Intellectual Property High Court of the patent infringement lawsuit regarding the generic drugs to an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5μg / 0.75μg (generic name: eldecalcitol, hereafter, Edirol Capsule) that was notified in the "Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit concerning Edirol Capsules" dated May 27, 2022.

1. The Court and Date of Appeal
   The Intellectual Property High Court, June 9, 2022
2. Reasons for the Appeal
   As Chugai announced in the "Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit concerning Edirol Capsules" dated May 27, 2022, the Tokyo District Court rendered judgment to dismiss the plaintiff's claim in the lawsuit filed by Chugai on May 29, 2020 against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. After consideration of the written judgment in detail, Chugai has determined to appeal the Tokyo District Court's decision.
3. Defendants

(1) Name:	Sawai Pharmaceutical Co., Ltd.
Address:	5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan
(2) Name:	Nichi-Iko Pharmaceutical Co., Ltd.
Address:	1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan

4. Prospects

No changes are expected to Chugai's financial prospects at this point.

###